# Four compounds, four different economics

> Compare Retatrutide, Tirzepatide, BPC-157 & CJC-1295 | Peptide Discount Shop — A side-by-side comparison of retatrutide, tirzepatide, BPC-157 and CJC-1295 — mechanism, regulatory status, evidence maturity, and why synthesis complexity drives cost.

**Compare**

Mechanism, evidence maturity and regulatory status side by side — and why synthesis complexity, not marketing, drives most of the price spread.

## How these four compounds differ

The four compounds on this site were chosen because they sit at genuinely different points on both the evidence-maturity axis and the synthesis-complexity axis, and those two axes explain most of what a reader needs to know before taking any claim about them at face value. Retatrutide and tirzepatide are large, chemically modified peptides built around the same fatty-diacid acylation strategy for a long half-life; tirzepatide has cleared FDA approval and carries the deepest published trial record of the group, while retatrutide is still in Phase 3 trials but has already shown larger weight-loss and liver-fat effects in Phase 2 data [3][4]. BPC-157 and CJC-1295 are both unapproved research chemicals with far thinner human evidence — BPC-157's human data are limited to three small pilot studies [14], and CJC-1295's human evidence is restricted to early pharmacology work in small groups of healthy adults [21][22].

## Mechanism, side by side

| Compound | Category | Regulatory status | Evidence maturity | Primary research focus | Relative synthesis complexity |
|---|---|---|---|---|---|
| Retatrutide | Triple GIP/GLP-1/glucagon receptor agonist | Investigational (Phase 3) | Multiple published Phase 1/2 human trials [1][4][5][6] | Weight loss, liver fat, metabolic markers | High — fatty-diacid acylated, 39 residues |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | FDA-approved (T2D, obesity) | Deepest record of the four, incl. head-to-head trial [8][11][12] | Weight loss, glycemic control | High — fatty-diacid acylated, 39 residues |
| BPC-157 | Gastric-derived pentadecapeptide | Not approved anywhere | Overwhelmingly preclinical; 3 small human pilots [14] | Tissue repair, angiogenesis (animal models) | Low — short 15-residue linear chain |
| CJC-1295 | GHRH analog (DAC / no-DAC) | Not approved anywhere | Early-phase human pharmacology only [20][21][22] | GH/IGF-1 axis elevation | Moderate–High — DAC form adds albumin-binding linker |

## Why the price gap tracks the evidence gap — and why it shouldn't be read as a guarantee

It is tempting to read a higher price as a stand-in for better quality, and a lower price as a warning sign — but the honest picture is more limited than that. Price differences across this group track synthesis complexity (a short 15-residue chain like BPC-157 is cheaper to make than a 39-residue fatty-acid-conjugated molecule like retatrutide or tirzepatide), purity-testing rigor, and cold-chain handling, none of which is visible on a product page. A cheap, short peptide can still be well-tested, and an expensive, complex one can still be poorly verified. The only way any of this becomes trustworthy is independent purity and identity testing — something no price point guarantees on its own. This is why every compound page on this site separates cited clinical findings from anecdotal community reports and from open safety questions: the label 'expensive' or 'cheap' tells you about manufacturing cost structure, not about what is actually in the vial.

---

This is a literature briefing on research-peptide economics, not a shop, a clinic, or a source of dosing instructions.